{"id":"vincristin-adriamycin-dexamethasone-vad","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vincristine's mechanism of action is through the inhibition of microtubule formation, which disrupts cell division and leads to cell death. Adriamycin's mechanism of action is through the intercalation of DNA, which inhibits topoisomerase II and induces DNA damage, ultimately leading to cell death. Dexamethasone's mechanism of action is through the suppression of inflammation and immune response, which can help to reduce swelling and alleviate symptoms.","oneSentence":"Vincristine is a vinca alkaloid that inhibits microtubule formation by binding to tubulin, disrupting cell division. Adriamycin is an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and inducing DNA damage. Dexamethasone is a corticosteroid that suppresses inflammation and immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:39.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Hodgkin's lymphoma"},{"name":"Non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT00002878","phase":"PHASE3","title":"Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-06-30","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00054158","phase":"PHASE2","title":"Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2004-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":24},{"nctId":"NCT01255514","phase":"PHASE2","title":"Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-10-30","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT00580372","phase":"PHASE2","title":"UARK 89-001 Phase II Study of Intensive \"TOTAL THERAPY\" For Untreated or Minimally Treated Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2002-08","conditions":"Multiple Myeloma","enrollment":231},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT00215943","phase":"PHASE3","title":"Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2003-06","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00441168","phase":"PHASE2","title":"Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma","status":"TERMINATED","sponsor":"Janssen-Cilag International NV","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT00006232","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma","status":"COMPLETED","sponsor":"West of Scotland Lymphoma Group","startDate":"1996-10","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":200},{"nctId":"NCT00344422","phase":"PHASE3","title":"Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-10","conditions":"Multiple Myeloma, Myeloma, M-Protein","enrollment":198},{"nctId":"NCT01370434","phase":"PHASE2","title":"Two Cycles of PAD Combination by AHCT in MM","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2006-07","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT01070862","phase":"PHASE3","title":"Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2003-05","conditions":"Multiple Myeloma de Novo Treatment","enrollment":""},{"nctId":"NCT00285389","phase":"PHASE2","title":"Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2002-02","conditions":"Mantle Cell Lymphoma","enrollment":39},{"nctId":"NCT00200681","phase":"PHASE3","title":"IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2005-06","conditions":"Multiple Myeloma","enrollment":493},{"nctId":"NCT00378755","phase":"PHASE2","title":"Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM","status":"UNKNOWN","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":166,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vincristin , Adriamycin, Dexamethasone = VAD","genericName":"Vincristin , Adriamycin, Dexamethasone = VAD","companyName":"University Hospital, Caen","companyId":"university-hospital-caen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vincristine is a vinca alkaloid that inhibits microtubule formation by binding to tubulin, disrupting cell division. Adriamycin is an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and inducing DNA damage. Dexamethasone is a corticosteroid that suppresses inflammation and immune response. Used for Multiple myeloma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}